Dermata Therapeutics, Inc.
DRMA
$1.29
$0.1210.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.33M | 4.84M | 4.48M | 4.05M | 3.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.36M | 7.77M | 9.07M | 10.54M | 11.65M |
| Operating Income | -7.36M | -7.77M | -9.07M | -10.54M | -11.65M |
| Income Before Tax | -7.10M | -7.56M | -8.85M | -10.33M | -11.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.10 | -7.56 | -8.85 | -10.33 | -11.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.10M | -7.56M | -8.85M | -10.33M | -11.46M |
| EBIT | -7.36M | -7.77M | -9.07M | -10.54M | -11.65M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -6.44 | -10.43 | -17.95 | -36.72 | -75.87 |
| Normalized Basic EPS | -4.03 | -6.52 | -11.22 | -22.95 | -47.42 |
| EPS Diluted | -6.44 | -10.43 | -17.95 | -36.72 | -75.87 |
| Normalized Diluted EPS | -4.03 | -6.52 | -11.22 | -22.95 | -47.42 |
| Average Basic Shares Outstanding | 6.65M | 3.31M | 2.52M | 1.65M | 1.08M |
| Average Diluted Shares Outstanding | 6.65M | 3.31M | 2.52M | 1.65M | 1.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |